Pfizer's sigvotatug vedotin fails Phase 3 lung cancer trial, the third Seagen-acquired ADC to disappoint in roughly a year.
Albert Bourla, Pfizer CEO (AP Photo/Markus Schreiber)
June 23, 2026 10:44 AM EDTUpdated 12:29 PM
R&DPharma
Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial
Elizabeth Cairns
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
Pfizer's Lung Cancer Drug Candidate Falls Short Overall, Shows Benefit In Select Patients - Pfizer (NYSE:
Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Amid safety concerns, ADC Therapeutics plots 17% staff cuts to push resources behind Zynlonta
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
Alnylam scolded over promotional activity after Pfizer complaint
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are…
Pfizer's sigvotatug vedotin missed its Phase 3 OS goal in NSCLC but showed encouraging results in second-line patients.
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
